Key result
Omega-3 fatty acids administered at 4 g daily for 12 weeks significantly reduced small dense LDL proportions by 11% and decreased apolipoprotein B levels in type 2 diabetic patients.
Why the study?
Does omega-3 fatty acids improve plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia?
RCT (n=28)
Double-blind
Randomized
Yes
Does omega-3 fatty acids improve plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia?
High-dose omega-3 fatty acid supplementation reduces atherogenic sdLDL and apolipoprotein B levels in type 2 diabetic patients with hypertriglyceridemia, though it may increase fasting blood glucose.
Answers are grounded in this paper and cite their sources.
Supports high-dose omega-3 in T2DM with hypertriglyceridemia; extends RCT evidence on sdLDL/apoB reduction while advising glycemic monitoring.
Background: Omega-3 fatty acids derived from fish oil have been reported to exert a beneficial effect on reducing cardiovascular disease.Reports about their mechanism have generated several interesting findings, including a change in small dense low density lipoprotein (sdLDL) cholesterol proportion, adiponectin, and apolipoprotein B (apoB), in addition to changes in the lipid profile.The principal objective of our study was to evaluate the effects of omega-3 fatty acids on plasma sdLDL, adiponectin, apoB100, and B48 in type 2 diabetic patients with hypertriglyceridemia. Methods: We randomized 28 type 2 diabetic patients in a placebo-controlled, double-blind trial to receive either omega-3 fatty acids or placebo, both administered at a dose of 4 g daily for 12 weeks.LDL subfractions prior to and after treatment were separated via low-speed ultracentrifugation and analyzed via immunoelectrophoresis.Adiponectin, apoB100, and B48 levels were measured using an ELISA kit.Results: sdLDL proportions were reduced in the omega-3 fatty acids group by 11% after 12 weeks of treatment (n = 17, P = 0.001), and were reduced by 4% in the control group (n = 11, P = 0.096).The patients receiving the omega-3 fatty acids evidenced a significant reduction in the levels of triglyceride (P = 0.001), apoB100, and B48 after 12 weeks (P = 0.038 and P = 0.009, respectively) relative to the baseline.Omega-3 fatty acids supplementation increased fasting blood glucose (P = 0.011), but the levels of HbA1c in each group did not change to a statistically significance degree.The adiponectin value was not reduced in the omega-3 fatty acids group (P = 0.133); by way of contrast, the placebo group evidenced a significant reduction in adiponectin value after 12 weeks (P = 0.002).Conclusion: Omega-3 fatty acid treatment proved effective in the reduction of atherogenic sdLDL and apoB in type 2 diabetic patients (Clinical trials reg.no.NCT 00758927, clinicaltrials.gov).
No takes yet. Share an insight, caveat, or question.
Jun et al. (2011) conducted an RCT in Type 2 Diabetes with Hypertriglyceridemia (n=28). Omega-3 fatty acids vs. Placebo was evaluated on Small dense LDL (sdLDL) proportion (p=0.001). Omega-3 fatty acids administered at 4 g daily for 12 weeks significantly reduced small dense LDL proportions by 11% and decreased apolipoprotein B levels in type 2 diabetic patients.
Synapse has enriched 10 related papers. Consider them for comparative context: